bariatric surgery glp-1 Choosing Between Weight Loss Medications and Differences on GLP-1 secretion and

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

Uitsluitend op recept.

The global appetite for GLP-1 medications like Ozempic, Wegovy and Mounjaro have created something far more dangerous than a cultural trend

Currently, the Food and Drug Administration (FDA) has approved seven GLP-1 prescription medications:GENERIC NAMEBRAND NAMEFORMSSemaglutideOzempicRybelsusWegovyInjectionOral PillTirzepatideMounjaroZepboundInjectionLiraglutideVictozaSaxendaInjectionDulaglutideTrulicityInjectionExenatideByettaInjectionLixisenatideAdlyxinInjectionOrforglipron*Foundayo*Oral Pill*Non-peptide, small molecule When used in addition to a reduced calorie diet and increased physical activity, these medications are FDA approved for one or more of the following:Improving blood sugar levels in adults with T2D.Reducing excess body weight and keep it off long term in:Adults and children aged 12 years and older with obesity.Adults who are overweight who also have at least one weight-related medical problem (such as high blood pressure, diabetes, or high cholesterol)Reducing the risk of major adverse cardiovascular events in adults with T2D who have heart disease or are at high risk for these events.Can Service Members use GLP-1 prescription medications?GLP-1 medications are only available with a prescription from a qualified healthcare provider

Hosted by obesity rights advocate advocate Amanda Bonello, the GLP-1 Studio Podcast is where science, lived experience, and a little bit of I cannot believe we have to fight this hard for healthcare energy all come together